Comparison of complications during 1-year follow-up between remitting seronegative symmetrical synovitis with pitting edema syndrome and elderly-onset rheumatoid arthritis.
RS3PE
corticosteroid
infection
remitting seronegative symmetrical synovitis with pitting edema
syndrome
Journal
Immunological medicine
ISSN: 2578-5826
Titre abrégé: Immunol Med
Pays: England
ID NLM: 101736847
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
pubmed:
5
4
2022
medline:
2
9
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE), a rheumatic disease affecting the elderly, responds well to corticosteroids; however, our RS3PE patients' corticosteroid therapy is longer than expected. Elderly-onset rheumatoid arthritis (EORA) patients are reported to be at a significantly increased risk for steroid-related side effects including cardiovascular diseases (CVDs). To clarify the complications during a 1-year follow-up in corticosteroid-treated RS3PE patients compared to EORA patients. We retrospectively analyzed the records of 47 RS3PE patients (28 men, 19 women, age 78.4 ± 7.5 years) and 46 EORA patients (10 men, 36 women; 77.0 ± 6.8 yrs) to compare the complications over a 1-year follow-up. The RS3PE and EORA groups' average initial PSL doses were 16.5 ± 7.2 mg/day and 7.3 ± 4.6 mg/day, respectively. During the 1-year follow-up after treatment, there was no significant increase in CVDs in both groups. However, infections occurred in nine RS3PE patients, which is a significantly higher incidence compared to the EORA patients with infections (
Identifiants
pubmed: 35369853
doi: 10.1080/25785826.2022.2046307
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM